Yarrow Bioscience (VYNE) awards 185,798 stock options to director Tyler

Rhea-AI Filing Summary

Zeronda Tyler, a director of Yarrow Bioscience, Inc., received a grant of stock options covering 185,798 shares of common stock on July 27, 2026. The options have an exercise price of $28.56 per share, expire on July 27, 2036, and vest one quarter on July 27, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Zeronda Tyler

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	185,798	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 185,798 shares (Direct)

Footnotes (1)

1. F1. This option represents a right to purchase 185,798 shares of the Issuer's common stock, one quarter of which will vest on July 27, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

Stock options granted: 185,798 shares Exercise price: $28.56 per share Option expiration date: July 27, 2036 +2 more

5 metrics

Stock options granted 185,798 shares Director Zeronda Tyler grant on July 27, 2026

Exercise price $28.56 per share Exercise price of granted stock options

Option expiration date July 27, 2036 Expiration of director stock option grant

Underlying common shares 185,798 shares Shares of common stock subject to the option

Initial vesting date July 27, 2027 One quarter of the option vests on this date

Key Terms

Stock Option (Right to Buy), underlying security, vesting

3 terms

Stock Option (Right to Buy) financial

"Security title reported as Stock Option (Right to Buy)"

underlying security financial

"Underlying security title disclosed as Common Stock"

vesting financial

"one quarter of which will vest on July 27, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/29/2026 - 09:34 PM Accepted by SEC EDGAR 07/29/2026 - 09:33 PM Learn about SEC filing dates

FAQ

What insider transaction involving VYNE did Yarrow Bioscience report for Zeronda Tyler?

Yarrow Bioscience reported that director Zeronda Tyler received a grant of 185,798 stock options on July 27, 2026. These options cover the company’s common stock and represent a compensation-related grant/award acquisition, not an open-market purchase or sale.

What are the key terms of Zeronda Tyler’s 185,798 Yarrow Bioscience (VYNE) stock options?

The grant covers 185,798 options with an exercise price of $28.56 per share, expiring on July 27, 2036. Each option is a right to buy Yarrow Bioscience common stock under the specified vesting schedule and price.

How do the stock options granted to Zeronda Tyler in VYNE vest over time?

The options vest in stages: one quarter vests on July 27, 2027, and the remaining three quarters vest in equal monthly installments over the following three years. Vesting is conditioned on continued service with Yarrow Bioscience.

Was Zeronda Tyler’s Form 4 option grant in Yarrow Bioscience (VYNE) made under a Rule 10b5-1 plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and the option grant is reported as a compensation-related award rather than a transaction executed under a pre-arranged trading plan.

How many Yarrow Bioscience (VYNE) shares could Zeronda Tyler acquire if all granted options are exercised?

If fully vested and exercised, the stock option grant allows acquisition of 185,798 shares of Yarrow Bioscience common stock. Actual ownership will depend on vesting, continued service, and any future exercises of these options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zeronda Tyler

(Last) (First) (Middle)

C/O YARROW BIOSCIENCE, INC.

470 JAMES STREET, SUITE 007

(Street)

NEW HAVEN CONNECTICUT 06513

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Yarrow Bioscience, Inc. [ YARW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$28.56	07/27/2026		A		185,798		(1)	07/27/2036	Common Stock	185,798	$0	185,798	D

Explanation of Responses:

1. This option represents a right to purchase 185,798 shares of the Issuer's common stock, one quarter of which will vest on July 27, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Tyler Zeronda	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)